NCT04620187 2026-04-13
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
15 trialsNCT05408845 2026-04-03
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04893109 2026-02-24
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06595563 2026-02-19
ZEPHIR-02
Jules Bordet Institute
Phase 2 Recruiting
NCT06348134 2026-02-17
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
Phase 2 Recruiting
NCT07389876 2026-02-05
G/GEJ
Fudan University
Recruiting
NCT05673928 2026-01-21
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06439693 2025-06-26
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05525858 2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting
NCT05288777 2025-04-18
Breast53
University of Virginia
Phase 2/3 Recruiting
NCT04680442 2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2 Recruiting
NCT06125834 2024-04-16
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting